The Antifungal and Antibiofilm Activities of Caffeine against Candida albicans on Polymethyl Methacrylate Denture Base Material.

BACKGROUND: In this study, the effect of pure caffeine was established against Candida albicans (C. albicans) using different microbiological techniques. METHODS: Broth microdilution and colony forming units (CFUs) assays were used to detect the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC). The Live/Dead fluorescent dyes were implemented to determine the yeast viability. Polymethyl methacrylate acrylic resin (PMMA) discs were prepared to evaluate caffeine's effects against adherent C. albicans using microplate reader, CFUs, and scanning electron microscope (SEM). RESULTS: caffeine's MIC was detected around 30 mg/mL, while the MFC was considered at 60 mg/mL. In an agar-well diffusion test, the inhibition zones were wider in caffeine groups. The Live/Dead viability test verified caffeine's antifungal effects. The optical density of the adherent C. albicans on PMMA discs were lower at 620 nm or 410 nm in caffeine groups. CFU count was also reduced by caffeine treatments. SEM revealed the lower adherent C. albicans count in caffeine groups. The effect of caffeine was dose-dependent at which the 60 mg/mL dose demonstrated the most prominent effect. CONCLUSION: The study reinforced caffeine's antifungal and antibiofilm properties and suggested it as an additive, or even an alternative, disinfectant solution for fungal biofilms on denture surfaces.

Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus.

Oral lichen planus (OLP), a mucocutaneous chronic inflammatory disease, is conventionally managed using topical corticosteroid therapy. Given the fact that OLP is strongly linked to angiogenesis, anti-angiogenic drugs, such as bevacizumab, might be introduced as an alternative treatment for contraindicated, non-responsive patients. The aim of the present study was to report the short-term effectiveness and safety of intralesional bevacizumab injection in the management of atrophic/erosive OLP. A case series study was conducted in patients with atrophic/erosive OLP in the buccal mucosa, assigned to receive either 2.5 mg of bevacizumab, by intralesional injection (n = 20, test), or topical 0.1% triamcinolone acetonide ointment (n = 20, control). The size, score, and pain intensity of the lesions were assessed pre- and post-treatment. Tissue biopsies were collected for histopathologic, immunohistochemical, and ultrastructural examination. After 1 wk, the test group had significant reductions both in lesion seize and in pain scores compared with controls. A marked decrease in vascular endothelial growth factor (VEGF) and interleukin-8 immunoexpression was noted in tissue biopsies from bevacizumab-treated lesions compared with control lesions. Furthermore, ultrastructural examination of OLP tissue specimens revealed significant healing signs associated with bevacizumab treatment. Short-term data suggest that intralesional bevacizumab injection effectively and safely achieved resolution of atrophic/erosive OLP lesions without disease exacerbations during a 3-month follow-up period.

Enhanced Periodontal Regeneration by Novel Single Application Sustained Release Nano-Structured Doxycycline Films.

The use of different drug classes as host modulating agents has been postulated to have significance as an adjunctive remedy curing chronic periodontitis. In this study nano-structured films containing doxycyclin (DOX) were evaluated for such purpose. Nano DOX/chitosan particulate system was prepared using spray drying technique and was then incorporated in PVA-based films. The particles were evaluated for particle size, zeta potential and possible drug/polymer interaction. The films were also tested for in-vitro drug release and clinical efficacy compared with placebo and DOX-loaded films. The formed particles had a zeta potential of + 13.8 mV and particle size of 52.86 nm with a polydispersity of PDI=0.946. No significant drug/polymer interaction was detected by DSC thermal analysis. In-vitro DOX release was sustained for about a week with the nano-structured films showing 23% of the drug released compared with 44% released from DOX films. Clinical efficacy was done on 150 periodontal pockets from patients suffering from moderate chronic periodontitis. Following scaling and root planning they were divided into three groups; group I receiving nano-structured (DOX), group II receiving DOX and group III receiving placebo films. Evaluation was done both clinically and biochemically at base-line, 1 week, 1 month and 2 months following drug application. Clinical findings indicated a significant effect of both nano-structured and DOX films in improving the measured parameters compared with the control and placebo groups.